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A 66-year old female with HIV-negative classic Kaposi’s sarcoma responded to mTOR targeting by rapamycin. The response
was well documented by PET-CT. This case provides supporting evidence that the mTOR pathway may be important in the
tumorigenesis of KS and that rapamycin may have activity in this disease.
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1. INTRODUCTION
Kaposi’s sarcoma (KS) is an indolent vascularized tumor that
has been subdivided into several variants including classic
KS, African endemic KS, iatrogenic (post transplantation)
KS, and epidemic, acquired immunodeﬁciency syndrome-
associated (AIDS-associated) KS. It behaves more aggres-
sively in HIV-related or in post transplant patients, but
its classic form may be more indolent although disﬁguring
does not commonly result in early mortality. Clinically, KS
forms dark blue or purplish macular lesions or spindle-
shaped nodular lesions that occur in the skin, lymphoid,
respiratory, and gastrointestinal tissues. Histological picture
shows networks of spindle-shaped cells and vascular spaces
surroundedbyanendothelialcelllayer.Therapyforlocalized
disease is surgery or radiation therapy, while widespread
disease may be treated by systemic chemotherapy [1]. A
novel approach for the treatment of iatrogenic KS is mTOR
targeting by rapamycin. Rapamycin is currently available as
an antirejection agent and may be also used as antitumoral
therapy [2, 3]. In this paper, we report a case of HIV-negative
classic KS, which responded to mTOR targeting.
2. CLINICAL CASE
A 66-year old otherwise healthy Caucasian female patient
presented with metastatic HIV-negative Kaposi’s sarcoma
(KS), diﬀusely involving the skin and soft tissues of the
plantar surface, legs, and thighs. During a prolonged interval
of palliative radiation therapy and various ineﬀective sys-
temic chemotherapeutic regimens that included vinblastine,
etoposide, doxorubicin, and alpha-interferon. The disease
progressed and spread to the bowel and to the soft tissues
of the left arm and to the inguinal, mediastinal, axillary,
and cervical nodes. Clinically, the patient had a Karnofsky’s
performancestatusof80–70%,andcomplainedofweakness,
and pain in her lower limbs. Radiologically, the disease was
welldocumentedbyPET-CTperformedonOctober18,2006
(Figure 1). After obtaining a local IRB approval and signing
an informed consent, oral rapamycin was started according
to the following schedule: 1mg daily in the 1st week, 1mg
twice daily in the 2nd week, 1mg three times daily in the 3rd
week, and then 1week oﬀ. The next 28-day cycles included
oral rapamycin 1mg three times daily for 3 out of 4weeks.
No serum level of rapamycin was obtained as in cases of
organ transplantation. After a 4-week uneventful induction,
she moved to 3mg daily rapamycin. Side eﬀects included
anemia (Hb 9.8gr/dl), weakness, and mild stomatitis. On
January 2007, about 3months after treatment initiation,
the soft tissue lesions partially regressed, and the patient
mentioned itching in the legs and trunk. PET-CT, performed
attheendofJanuary2007,demonstratedsigniﬁcantdecrease
i nF D Gu p t a k ei na l m o s ta l li n v o l v e ds i t e s( Figure 1). The
patient is still on treatment for almost 12months now.
3. DISCUSSION
Our case points to two important observations. First is
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Figure 1: PET-CT at initiation and at completion of almost 4-month rapamycin therapy.Ofer Merimsky et al. 3
classic KS. We observed that rapamycin monotherapy was
more active and better tolerated than systemic, conventional
chemotherapy in this patient. The second is monitoring
of the objective response by PET-CT imaging. The clinical
improvementcorrelatedwithmetabolicshutdownofglucose
metabolism in the sarcoma nodules, as documented by
decrease in FDG uptake. PET-CT as a tool for staging
and monitoring of therapy has been suggested for vascular
tumors [4].
Rapidly accumulating data implicate rapamycin, a nat-
ural product produced by Streptomyces hygroscopicus as
a potential anticancer agent. While originally identiﬁed
20years ago during antibiotic screening and found to display
remarkable antifungal activity, rapamycin was subsequently
recognized to possess highly potent immunosuppressive
properties[5]andhassincebeenusedasthedrugofchoicein
organ transplantation. More recently, the growth inhibitory
eﬀects of rapamycin have been recognized alongside the
elucidation of the molecular basis of its function. The
ultimate cellular target of rapamycin has been identiﬁed as
a signaling kinase named “mTOR” (mammalian target of
rapamycin), a member of the phosphatidylinositol-3-kinase
(PI3K)-related kinases (PIKKs). The PIKK family members,
also including the ATM kinase, are involved in the control
of essential cell functions, including cell-cycle progression,
cell-cyclecheckpoints,DNArepair,andDNArecombination
[6]. Speciﬁcally, mTOR is a downstream component in the
PI3K/Akt (protein kinase B) pathway, which participates in
the activation of the p70S6 kinase (p70S6k). In response
to mitogenic stimuli, PI3K is activated resulting in a rise
in the cellular concentration of PIP3.T h i si nt u r nl e a d s
to activation of Akt followed by activation of mTOR.
MTOR then phosphorylates and activates p70S6k, the kinase
which phosphorylates the ribosomal protein S6 thereby
promoting the recruitment of the 40S subunit into actively
translating polysomes [7]. Following mitogenic stimulation
and activation of mTOR, the latter also phosphorylates the
4E-binding protein-1 (4E-BP1). The latter binds tightly to
eIF-4E thereby preventing initiation of translation. However,
upon its mTOR-mediated phosphorylation, 4E-BP1 dissoci-
ates thereby allowing eIF-4E to bind to the eIF-4F complex
and translation increases [8, 9]. Therefore, mTOR activation
results in the transduction signaling events that ultimately
activate cyclin-dependent kinases (CDKs), increase cellular
levels of cyclins such as cyclin D1, and promote retinoblas-
toma (Rb) protein phosphorylation. As such, mTOR plays a
central role in the control of cell proliferation, cell survival,
and adhesion-independent survival and migration [10, 11].
Rapamycin binds to its intracellular receptor protein
FKBP12 [12], forming a complex, which then binds to
and inhibits the function of mTOR [12]. Through mTOR
inhibition, rapamycincausescellcyclearrestintheG1phase,
prevents CDK activation, inhibits Rb protein phosphory-
lation, and accelerates the turnover of cyclin D1, leading
to a deﬁciency of active CDK4/cyclin D1 complexes. These
events then contribute to the prominent inhibitory eﬀects
of rapamycin at the G1/S boundary of the cell cycle [13].
Notably, rapamycin also displays antiangiogenic activities
linked to a decrease in production of vascular endothelial
growth factor (VEGF) thereby markedly inhibiting response
of vascular endothelial cells to stimulation by VEGF [14].
The antiproliferative activity of rapamycin was ﬁrst eval-
uated in variety of murine tumor cell lines and tumor model
systems. In those experiments, rapamycin was found to
exhibit impressive antitumor activity inhibiting the growth
of lymphoma cell lines, small cell lung cancer cell lines,
rhabdomyosarcomacelllines,pancreaticcancercelllinesand
more (reviewed in [15]). Moreover, rapamycin augmented
cisplatin-induced apoptosis [16] and conferred radiation
sensitivity to otherwise resistant tumor cell lines [17]. Taken
together, these results suggest that rapamycin has both
intrinsic antiproliferative activity against a broad range of
cancers and the ability to synergize and enhance eﬃcacy
of cytotoxic agents [18]. Indeed, clinical trials of CCI-779
and Rad 001, structurally related analogs of rapamycin
with increased water solubility, are currently ongoing in
recurrent malignant glioma patients, in renal cell carcinoma,
metastatic pancreatic cancer, endometrial cancer, and more.
The role of mTOR signaling pathway in pathogenesis of
Kaposi’s sarcoma has been elucidated [19]. A human herpes
virus 8 (HHV8) or Kaposi’s sarcoma associated herpes virus
(KSHV) has been suggested as the etiological agent for
this tumor [20]. A single lytic gene, the KSHV G protein-
coupled receptor (vGPCR), a member of the family of
CXC chemokine GPCRs which exhibits ligand-independent
activity,hasbeenshowntoberesponsiblefortheinitiationof
KS [21]. Infection with KSHV is necessary and central to the
developmentofKS.KSHVinfectsKSspindleandendothelial
cells in KS lesions, seen eventually in all four forms of KS
(classic (Mediterranean), AIDS-related, endemic (African)
and iatrogenic) [22].
The discovery that the development of KS may be depen-
dent on vGPCR dysregulation suggests that the development
of new mechanism-based therapeutic modalities speciﬁcally
targeting this viral protein (or its downstream targets) may
prove to be an eﬀective treatment strategy [19]. Several
intracellular proteins, kinases, and transcription factors have
been shown to be involved in vGPCR-expressing cells [19].
It is believed that KSHV is the putative gene encoding the
vGPCR protein that is responsible for the development of
KS, via dysregulation mechanisms in certain circumstances
[19]. It has been suggested that anti-KS therapy might target
the viral protein or the downstream molecules involved in
the KS pathogenesis [19]. The vGPCR leads to activation
of the PI3K/Akt pathway [19]. Activation of Akt was found
to be involved in the protection of endothelial cells from
apoptosis, especially in KSVV-infected cells [19, 23]. AkT
plays an essential role in the activation of mTOR via
inactivation of tuberous sclerosis complex (TSC) [24, 25].
The TSC/mTOR pathway may play a critical role in the
developmentoftumorsdependentonAktactivation,andthe
pathwaymayberegulatedbyvGPCRviainactivationofTSC,
and consequent mTOR activation [19]. Other mechanisms
for KS genesis have also been suggested [19].
In conclusion, this case provides supporting evidence
that the mTOR pathway may be important in the tumori-
genesis of KS and that rapamycin may have activity in this4 Sarcoma
disease.AphaseIIstudyforassessingtheexactroleofmTOR
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